Search

Search Constraints

You searched for: Author/Creator Kleveland, Ola

Search Results

1. Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction. Issue 19 (21st April 2017)

2. Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction. (15th November 2018)

3. Novel Insights Into the Effects of Interleukin 6 Antagonism in Non–ST‐Segment–Elevation Myocardial Infarction Employing the SOMAscan Proteomics Platform. Issue 12 (16th June 2020)

4. Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI). Issue 2 (15th October 2019)

5. Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction. (1st January 2019)

6. Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction. Issue 2 (18th September 2018)

7. The IL-6 receptor inhibitor tocilizumab attenuated expression of C5a receptor 1 and 2 in patients with myocardial infarction. (September 2017)